首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1735607

2026 年至 2032 年疫苗市場規模（依疫苗類型、目標人口、通路和地區分類）

Vaccine Market Size By Type of Vaccine, By Target Population, By Channel of Distribution, And Region For 2026-2032

出版日期: 2025年05月02日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026-2032年疫苗市場評估

2024年，疫苗市場規模為463億美元，預計2032年將成長至704億美元，預測期內複合年成長率為8.11%。隨著大眾對疫苗可預防疾病的認知不斷提高，以及民眾對公共衛生的重視程度不斷提高，疫苗市場的需求正在成長。新冠疫情凸顯了疫苗接種在控制傳染病的重要性，並促使人們進一步研發新型疫苗。此外，政府對疫苗接種計畫的資金投入和支持力度不斷加大，也有助於推動市場擴張。

此外，疫苗需求正從感染疾病擴展到癌症和其他慢性疾病疫苗。這種轉變，加上疫苗研發和給藥技術的進步，預計將支撐疫苗市場未來的成長。

疫苗市場定義/概述

疫苗是生物製藥，用於誘發針對特定感染疾病的適應性免疫。它們通常由病原體的無害成分組成，例如減毒或去活化的病毒或遺傳物質片段。接種疫苗後，免疫系統會識別病原體，並在再次遇到病原體時發動攻擊。疫苗可以預防疾病、降低感染率並建立群體免疫力，保護因健康狀況而無法接種疫苗的人。

疫苗接種的原理是引入病原體的無害成分，例如減毒或去活化的病原體或其遺傳密碼片段，從而增強免疫系統，使其能夠在將來再次遇到病毒時快速有效地做出反應。疫苗接種有助於避免集體爆發，保護易感族群，並改善公共衛生。

疫苗接種的未來還包括個人化醫療的進步，即根據個人基因圖譜量身定做疫苗，以增強疫苗的有效性。 COVID-19 疫苗中展示的 mRNA 技術也可能被用於治療其他感染疾病和癌症。此外，人們正在嘗試生產針對流感等疾病的通用疫苗，這可能會提供更強大的保護。

預防保健意識的不斷提高如何促進疫苗市場的擴張？

預防保健意識的不斷增強，促進了疫苗業務的擴張，因為它鼓勵人們採取積極主動的健康管理方式。隨著越來越多的資料顯示疫苗接種在預防感染疾病具有益處，人們更有可能為自己和家人接種疫苗。公共衛生宣傳活動和教育計畫提高了人們對疫苗與疾病預防之間關聯的認知，從而增加了不同人群對疫苗的需求。這種預防趨勢鼓勵人們優先考慮自身健康，從而提高了疫苗接種率並擴大了市場。

此外，對預防性醫療保健的關注促使政府和企業增加了對疫苗研發的投資。對mRNA疫苗和病毒載體平台等新型疫苗技術的資助正在推動該領域的進步。隨著新疫苗的研發和上市，公眾興趣日益濃厚，需求不斷成長，疫苗產業也隨之擴張。對預防性干預措施的關注最終將減輕感染疾病的負擔，並改善整體公共衛生狀況。

疫苗研發成本高是否會阻礙疫苗市場的成長？

高昂的疫苗開發成本限制了能夠投資研發和生產的公司數量，嚴重限制了疫苗業務的擴張。開發一種新疫苗需要大量的資金投入，用於廣泛的研究、臨床試驗和合規性。這個過程可能需要數年時間，並且存在很大的不確定性，這使得中小企業難以與大型製藥公司競爭。因此，進入市場的新疫苗數量可能會減少，從而減緩整體成長並限制消費者的選擇。

此外，疫苗生產成本的上升可能會限制疫苗的取得，尤其是在中低收入國家。運輸和儲存疫苗需要低溫運輸物流，這會增加成本並使分發工作更加複雜。如此高成本結構可能會阻礙政府和醫療體系建立全面的疫苗接種計劃，阻礙感染疾病控制工作，並限制市場的成長潛力。

The vaccine market size was valued at USD 46.3 Billion in 2024 and is projected to grow 70.4 Billion by 2032, exhibiting a CAGR of 8.11% during the forecast period. The vaccine market is witnessing increased demand as people become more aware of vaccine-preventable diseases and place a greater emphasis on public health. The COVID-19 pandemic highlighted the necessity of vaccination in suppressing epidemics, prompting further research and development of new vaccines. Furthermore, increased government funding and support for immunization programs are fuelling market expansion.

Furthermore, vaccination demand is growing beyond infectious disorders to include therapeutic vaccines for cancer and other chronic illnesses. This transition together with technological advances in vaccine development and delivery technologies is projected to support the vaccine market's growth in the years ahead.

Vaccine Market: Definition/ Overview

A vaccination is a biological preparation that induces acquired immunity to a particular infectious disease. It usually comprises a harmless component of the pathogen such as a weakened or inactivated virus or a fragment of its genetic material. When vaccines are delivered, they stimulate the immune system to recognize and attack the pathogen if it is encountered again. Vaccination prevents illnesses, lowers transmission, and adds to herd immunity protecting people who are unable to be vaccinated due to medical conditions.

They function by introducing an innocuous pathogen component such as a weakened or inactivated form or a fragment of its genetic code. This exposure prepares the immune system to respond rapidly and efficiently if the body encounters the virus again in the future. Vaccination helps avoid outbreaks, protects vulnerable populations, and improves public health.

The future of vaccinations includes advances in personalized medicine in which immunizations are tailored to individual genetic profiles for increased efficacy. MRNA technology as demonstrated by COVID-19 vaccines will most likely be developed to treat other infectious diseases and cancer. In addition, attempts are underway to produce universal vaccinations for diseases such as influenza intending to provide greater protection.

How does Growing Awareness of Preventative Healthcare Contribute to the Expansion of the Vaccine Market?

A growing understanding of preventative healthcare helps to expand the vaccine business by encouraging a proactive approach to health management. As people learn more about the benefits of vaccination in preventing infectious diseases, they are more likely to seek immunizations for themselves and their families. Public health campaigns and educational programs have expanded awareness of the link between vaccines and illness prevention, resulting in increased demand for vaccines across various populations. This trend toward prevention encourages people to prioritize their health, which leads to higher vaccination rates and a larger market.

Furthermore, the emphasis on preventative healthcare has resulted in increasing government and corporate sector investment in vaccine research and development. Funding for novel vaccination technologies such as mRNA vaccines and viral vector platforms has spurred progress in this field. As new vaccines are developed and presented, they pique public interest, increasing demand and extending the vaccination industry. This emphasis on prevention interventions eventually reduces the burden of infectious diseases improving overall public health outcomes.

How Does the High Cost of Vaccine Development Serve as a Restraint on the Growth of the Vaccine Market?

The high cost of vaccine development severely limits the expansion of the vaccine business by limiting the number of companies capable of investing in research and production. Developing a novel vaccination necessitates significant financial investment for extensive research, clinical trials, and regulatory compliance. These processes can take years and involve a great deal of uncertainty making it difficult for smaller enterprises to compete with major pharmaceutical giants. As a result, fewer novel vaccines enter the market, potentially slowing overall growth and limiting customer alternatives.

Furthermore, the expense of vaccine manufacture might drive up costs, limiting access, especially in low- and middle-income nations. Transporting and storing vaccines requires cold chain logistics which raises costs and complicates distribution efforts. This high-cost structure may discourage governments and healthcare systems from establishing comprehensive immunization programs hamper efforts to control infectious illnesses, and restrict the market's potential for growth.

Category-Wise Acumens

How do Government Policies and Health Organizations Influence the Uptake of Pediatric Vaccinations?

Pediatric vaccines dominate the vaccine market owing to the increased need for immunization against numerous infectious diseases among children. Measles, mumps, rubella, polio, and hepatitis are all preventable diseases that require vaccination in childhood. Governments and health organizations prioritize kid immunization programs to ensure population health, resulting in broad vaccination campaigns. The implementation of routine vaccination schedules and mandated immunization laws in several countries has increased the demand for pediatric vaccinations.

Furthermore, as parents become more aware of the benefits of vaccinating their children, pediatric vaccinations have grown in popularity. Campaigns highlighting the value of immunization and addressing vaccine hesitancy have increased public trust in vaccination programs. As a result, pharmaceutical companies and healthcare providers are expanding their focus on producing and marketing pediatric vaccinations, resulting in large R&D investments. This emphasis guarantees that pediatric vaccinations remain an important component of the overall vaccine industry.

How do Healthcare Professionals in Hospitals and Clinics Educate Patients about the Benefits and Potential Side Effects of Vaccines?

Hospitals and clinics dominate the vaccine industry because of their critical role in delivering complete healthcare services. These facilities are key places of care for immunizations which are frequently included in ordinary healthcare practices. They provide a controlled environment for immunizations assuring safe storage, handling, and administration. Furthermore, hospitals and clinics frequently have access to a large patient population making it easier to run vaccination programs and campaigns efficiently.

Furthermore, hospitals and clinics are staffed with qualified healthcare experts who can educate people on the benefits of vaccines, address concerns, and manage potential adverse effects. Their established infrastructure facilitates the coordination of immunization schedules, record-keeping, and follow-up care. The emphasis on preventive healthcare in these contexts, particularly in reaction to epidemics or public health campaigns strengthens their position in the vaccine market by assuring high vaccination rates and successful immunization programs.

Country/Region-wise Acumens

How do Strong Research and Development Capabilities Impact the Diversity of Vaccines Available in the North American Region?

North America dominates the vaccination industry owing to its advanced healthcare infrastructure, strong research and development capabilities, and considerable financial investments in biotechnology. The region is home to major pharmaceutical businesses and research organizations that promote innovation and manufacture a diverse range of vaccines. Government support such as funding for vaccine development and public health programs boosts market growth as demonstrated during the COVID-19 pandemic.

Furthermore, North America has a strong distribution network that ensures vaccinations are stored and distributed under optimal circumstances, thereby preserving their potency. Public awareness campaigns and educational tools efficiently communicate the benefits of vaccines which boosts public trust. The region's response to recent health emergencies such as the COVID-19 pandemic, demonstrated its ability to quickly mobilize resources maintaining its leadership in the worldwide vaccination market.

How has the COVID-19 Pandemic Influenced Government Investments in Healthcare Infrastructure and Vaccination Initiatives in the Asia-Pacific Region?

Asia Pacific is the fastest-growing region in the vaccine market owing to a combination of reasons such as increasing population, rising healthcare expenditure, and increased awareness of the benefits of immunization. The region has a vast and diversified population which increases the demand for vaccines to treat a variety of infectious diseases. Furthermore, governments are investing heavily in healthcare infrastructure and vaccination initiatives to improve public health outcomes, particularly considering recent global health disasters such as the COVID-19 pandemic.

Furthermore, the rapid development of biotechnology and pharmaceutical industries in countries such as China and India improved vaccine production capacities and innovation. Collaborations between the public and private sectors accelerate research and development, resulting in the launch of new vaccinations. Furthermore, supporting government policies and initiatives focused on increasing immunization coverage and boosting healthcare access are driving market expansion in the Asia Pacific establishing the region as a worldwide vaccine industry leader.

Competitive Landscape

The Vaccine Market is a dynamic and competitive space characterized by diverse players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations focus on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the vaccine market include:

GSK plc, Merck & Co., Pfizer Inc., Sanofi, CSL Limited, Johnson & Johnson Services, AstraZeneca, Serum Institute of India Pvt Ltd, Bharat Biotech International Limited, Sinovac Biotech Ltd.

Latest Developments

In May 2024, Novavax and Sanofi disclosed a co-exclusive licensing agreement to co-commercialize a COVID-19 vaccine and collaborate on developing novel combination vaccines for COVID-19 and influenza. This strategic partnership allows both companies to leverage their respective expertise and resources to bring innovative vaccine solutions to the market. By joining forces, Novavax and Sanofi aim to enhance their competitive position in the rapidly evolving landscape of vaccine development and distribution.
In April 2023, Pfizer announced data from phase 3 trials of its RSV shots. The trial conducted in adult patients demonstrated that the shot was 67% more effective in preventing infections with two related symptoms and 86% effective in case of severe disease. The successful approval of this vaccine will make it the first product in the RSV market.

1 INTRODUCTION OF GLOBAL VACCINE MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL VACCINE MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL VACCINE MARKET, BY TYPE OF VACCINE

5.1 Overview
5.2 Preventive Vaccines
5.3 Therapeutic Vaccines
5.4 Recombinant Vaccines
5.5 Conjugate vaccines

6 GLOBAL VACCINE MARKET, BY TARGET POPULATION

6.1 Overview
6.2 Paediatric vaccines
6.3 Adult Vaccines
6.4 Vaccines for the Elderly
6.5 Travel vaccinations

7 GLOBAL VACCINE MARKET, BY CHANNEL OF DISTRIBUTION

7.1 Overview
7.2 Hospitals and Clinics
7.3 Retail Pharmacies
7.4 Government Programmes
7.5 Internet pharmacies

8 GLOBAL VACCINE MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa

9 GLOBAL VACCINE MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 GSK plc
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Merck & Co.
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Pfizer Inc.
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Sanofi
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 CSL Limited
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Johnson & Johnson Services
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 AstraZeneca
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Serum Institute of India Pvt Ltd
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Bharat Biotech International Limited
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Sinovac Biotech Ltd
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments